Bonville Cynthia A, Easton Andrew J, Rosenberg Helene F, Domachowske Joseph B
Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York 13210, USA.
J Virol. 2003 Jan;77(2):1237-44. doi: 10.1128/jvi.77.2.1237-1244.2003.
We report here the responses of mice with symptomatic pneumovirus infection to combined antiviral and specific immunomodulatory agents. Mice infected with pneumonia virus of mice, a natural mouse pathogen that replicates the signs and symptoms of severe infection with respiratory syncytial virus (RSV), responded to the antiviral agent ribavirin when it was administered in the setting of endogenous (gene deletion) or exogenous (antibody-mediated) blockade of the MIP-1alpha proinflammatory signaling cascade. Although neither treatment is effective alone, together they offer a dramatic reduction in symptoms and pathology, the most impressive of which is a significant reduction in morbidity and mortality. The findings presented are consistent with the notion of unique and independent contributions of virus replication and ongoing inflammation to the pathogenesis of severe respiratory virus infection, and they provide the impetus for the study of this treatment regimen in RSV-infected humans.
我们在此报告有症状的肺病毒感染小鼠对抗病毒和特异性免疫调节药物联合治疗的反应。感染小鼠肺炎病毒(一种天然的小鼠病原体,可复制严重呼吸道合胞病毒(RSV)感染的体征和症状)的小鼠,在内源性(基因缺失)或外源性(抗体介导)阻断MIP-1α促炎信号级联反应的情况下给予抗病毒药物利巴韦林时,会产生反应。虽然单独使用这两种治疗方法均无效,但联合使用可显著减轻症状和病理变化,其中最显著的是发病率和死亡率大幅降低。所呈现的研究结果与病毒复制和持续炎症对严重呼吸道病毒感染发病机制具有独特且独立作用的观点一致,并且为在感染RSV的人类中研究这种治疗方案提供了动力。